Arvinas (ARVN) Free Cash Flow (2017 - 2026)
Arvinas (ARVN) recorded quarterly Free Cash Flow of -$69.2 million in Q1 2026, down 126.14% quarter-over-quarter from -$30.6 million in Q4 2025, and up 22.25% on a YoY basis from -$56.6 million in Q1 2025.
Arvinas (ARVN) Free Cash Flow (2017 - 2026) Analysis & Trends
Arvinas' Free Cash Flow history runs 10 years deep, the most recent figure standing at -$69.2 million for Q1 2026.
- In Q1 2026, Free Cash Flow rose 22.25% year-over-year to -$69.2 million; the TTM figure through Mar 2026 stood at -$255.9 million (down 1.31% YoY), while the FY2025 annual figure was -$275.7 million, down 5.59% from the prior year.
- Free Cash Flow was -$69.2 million for Q1 2026 at Arvinas, down from -$30.6 million in the prior quarter.
- In the past five years, Free Cash Flow ranged from a high of $49.5 million in Q2 2024 to a low of -$128.7 million in Q3 2024.
- Historically, Free Cash Flow has averaged -$72.2 million across 5 years, with a median of -$80.3 million in 2023.
- The sharpest annual moves came in 2024 and 2025: Free Cash Flow surged 156.25% in 2024, then plunged 295.76% in 2025.
- A 5-year view of Free Cash Flow shows it stood at -$71.0 million in 2022, then declined by 13.1% to -$80.3 million in 2023, then slipped by 5.11% to -$84.4 million in 2024, then surged by 63.74% to -$30.6 million in 2025, then plunged by 126.14% to -$69.2 million in 2026.
- The last three Free Cash Flow figures came in at -$69.2 million (Q1 2026), -$30.6 million (Q4 2025), and -$59.2 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -1.67 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -12.20 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -2.49 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 1.29 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 63,220.27 |
| 10 | Arvinas | 492.16 Mn | -122.74 Mn | - | -69.20 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -69.20 Mn |
| Mar 31, 2026 | -69.20 Mn |
| Dec 31, 2025 | -30.60 Mn |
| Dec 31, 2025 | -30.60 Mn |
| Sep 30, 2025 | -59.20 Mn |
| Sep 30, 2025 | -59.20 Mn |
| Jun 30, 2025 | -96.90 Mn |
| Jun 30, 2025 | -96.90 Mn |
| Mar 31, 2025 | -89.00 Mn |
| Mar 31, 2025 | -89.00 Mn |
| Dec 31, 2024 | -84.40 Mn |
| Dec 31, 2024 | -84.40 Mn |
| Sep 30, 2024 | -128.70 Mn |
| Sep 30, 2024 | -128.70 Mn |
| Jun 30, 2024 | 49.50 Mn |
| Jun 30, 2024 | 49.50 Mn |
| Mar 31, 2024 | -97.50 Mn |
| Mar 31, 2024 | -97.50 Mn |
| Dec 31, 2023 | -80.30 Mn |
| Dec 31, 2023 | -80.30 Mn |